Mass vaccination against COVID-19 resumes in Olongapo City | Inquirer News

Mass vaccination against COVID-19 resumes in Olongapo City

COVID-19 vaccination at SMX Convention Center, SM Olongapo Central

A resident in Olongapo City gets inoculated against COVID-19 during a recent mass vaccination at the SMX Convention Center of SM Olongapo Central. (Photo courtesy of Olongapo City Information Center)

OLONGAPO CITY—The local government continued on Wednesday, July 21, its mass vaccination against COVID-19, administering another batch of the first doses of AstraZeneca, officials said.

At least 600 mostly priority residents received their first jabs of the AstraZeneca vaccine produced in the U.K.

ADVERTISEMENT

In a statement, Mayor Rolen Paulino Jr. said about 22,000 residents had been inoculated against COVID-19 since the city began its vaccine rollout.

FEATURED STORIES

But only about 11,000 of them had received their second dose due to the limited supply of vaccines.

Aside from AstraZeneca, the city has been administering the Coronavac vaccine made by the Chinese pharmaceutical firm Sinovac.

Olongapo has to inoculate 70 percent of its 260,000-population to achieve herd immunity against COVID-19.

lzb
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: AstraZeneca, COVID-19, Olongapo City, Regions

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.